{
  "docId": "019de076-48c2-7315-bf77-72d2721572a4",
  "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91",
  "documentTitle": "Immatics | Investor Presentation Deck | 75 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 75,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Data cut-off Sep 30, 2023. N=16 patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/21",
  "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4",
  "deckJsonHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4.json",
  "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.78
      },
      "kind": "callout",
      "text": "IMA203 GEN1 monotherapy continues to be well tolerated at total doses between 1-10x10^9 TCR-T cells (RP2D)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f4cf148-6362-42dc-bdb2-ba0cda3e9ac6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.08,
        "y": 0.33
      },
      "kind": "list",
      "text": "63% (10/16) with Grade 1 CRS\n31% (5/16) with Grade 2 CRS\n6% (1/16) with Grade 3 CRS (Phase 1a patient; recovered to Grade 2 after 3 days, no need for vasopressors and/or ventilation)\nNo dose-dependent increase of CRS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48f4e7b7-49f8-40ed-aaf4-efb90583dbb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Expected cytopenia (Grade 1-4) associated with lymphodepletion in all patients\nMostly mild to moderate cytokine release syndrome (CRS)\nOne non-serious, mild (Grade 1) ICANS in DL5\nNo dose-limiting toxicity\nNo IMA203-related deaths\nfull IMA203 GEN1 monotherapy safety profile (generally consistent with safety in melanoma subset), see next slide",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3db5bdd-97f6-4eda-b908-c1a1d8715b1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "N=16 Patients in Safety Population",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afe97dbc-87b4-4257-928c-50192ab5fbf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Three cutaneous melanoma patients treated with IMA203 and pending post infusion scan included in safety population, but not efficacy population; ICANS: Immune Effector Cell-Associated Neurotoxicity Syndrome; CRS and ICANS graded by CARTOX criteria (Neelapu et al., 2018)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef37182d-6994-4c6e-889b-f6e2a81fd3d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "IMA203 GEN1 in All Melanoma Patients at RP2D – Most Frequent Adverse Events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a00c7c35-9c1b-4b80-8e43-e53e0293a65b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "af2f4ecf-d203-4aa2-aa5e-20e174ea15e6",
      "evidence": "list/bullet: Expected cytopenia (Grade 1-4) associated with lymphodepletion in all patients",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 16,
      "beatId": "e53f0bdd-f989-4e54-a22e-36140cd1c7e7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction is presented in the traction and appendix data sections.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "89016a77-dafb-4a09-a082-b702ab9d3e72",
      "evidence": "The loop is visible in the section on delivering a meaningful benefit to patients with an unmet medical need.",
      "position": 0,
      "objective": "Highlight the unmet medical need",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}